Projecting direct medical costs and productivity benefits of improving access to advanced therapy for rheumatoid arthritis: a projection modelling study

References

• Harjit S, Gunn A, Abdul J, et al. NATIONAL HEALTHCARE ESTABLISHMENTS & WORKFORCE STATISTICS 2010. Chapter 5 | SURGICAL SERVICES IN MALAYSIAN HOSPITALS. 2010. http://www.crc.gov.my/nhsi/wp-content/uploads/publications/NHEWS_Hospital2010/Chapter5Hospitals_Report_2010.pdf
   Google Scholar
• Rudan I, Sidhu S, Papana A, et al. Prevalence of rheumatoid arthritis in low- and middle-income countries: a systematic review and analysis. J Glob Health. 2015 Jun;5(1):010409. DOI:10.7189/jogh.05.010409.
   PubMed Web of Science ®Google Scholar
• Hsieh PH, Wu O, Geue C, et al. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann Rheum Dis. 2020 Jun;79(6):771–10. DOI:10.1136/annrheumdis-2019-216243.
   PubMed Web of Science ®Google Scholar
• Ji J, Zhang L, Zhang Q, et al. Functional disability associated with disease and quality-of-life parameters in Chinese patients with rheumatoid arthritis. Health Qual Life Outcomes. 2017 May 2;15(1):89. DOI:10.1186/s12955-017-0659-z.
   PubMedGoogle Scholar
• Shanahan EM, Smith MD, Roberts-Thomson L, et al. The effect of rheumatoid arthritis on personal income in Australia. Intern Med J. 2008 Jul;38(7):575–579. DOI:10.1111/j.1445-5994.2007.01546.x.
   PubMed Web of Science ®Google Scholar
• Merkesdal S, Ruof J, Schoffski O, et al. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum. 2001;44(3):528–534.
   PubMedGoogle Scholar
• van Vilsteren M, Boot CR, Knol DL, et al. Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord. May 6 2015;16:107. DOI:10.1186/s12891-015-0562-x.
   PubMed Web of Science ®Google Scholar
• Callhoff J, Weiss A, Zink A, et al. Impact of biologic therapy on functional status in patients with rheumatoid arthritis–a meta-analysis. Rheumatology (Oxford). 2013 Dec;52(12):2127–2135. DOI:10.1093/rheumatology/ket266.
   PubMed Web of Science ®Google Scholar
• Iragorri N, Hofmeister M, Spackman E, et al. The effect of biologic and targeted synthetic drugs on work- and productivity-related outcomes for patients with psoriatic arthritis: a systematic review. J Rheumatol. 2018 Aug;45(8):1124–1130. DOI:10.3899/jrheum.170874.
   PubMed Web of Science ®Google Scholar
• Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 2012 Dec;51(Suppl 6):vi28–36.
   PubMed Web of Science ®Google Scholar
• Merih B, Sedat Ç, Servet A, et al. Comparison of glucocorticoid and nonsteroidal anti-inflammatory drug requirement before and after tumor necrosis factor inhibitor treatment in patients with rheumatoid arthritis. Arch Rheumatol. 2015;30(3):206–213.
   Web of Science ®Google Scholar
• Shahrir M, Shahdan M, Shahid M, et al. Multicentre survey of rheumatoid arthritis patients from ministry of health rheumatology centers in Malaysia. Int J Rheum Dis. 2008;11(3):287–292. DOI:10.1111/j.1756-185X.2008.00379.x
   Web of Science ®Google Scholar
• de Camargo MC, Barros BCA, Fulone I, et al. Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting. Front Pharmacol. 2019;10:965. https://pubmed.ncbi.nlm.nih.gov/31572173/.
   PubMed Web of Science ®Google Scholar
• Haagsma CJ, van Riel Pl, de Jong AJ, et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997 Oct;36(10):1082–1088. DOI:10.1093/rheumatology/36.10.1082.
   PubMedGoogle Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010 Jan;69(1):88–96. DOI:10.1136/ard.2008.105197.
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. Jun 19 2014;370(25):2377–2386. DOI:10.1056/NEJMoa1310476.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. Feb 16 2017;376(7):652–662. DOI:10.1056/NEJMoa1608345.
   PubMed Web of Science ®Google Scholar
• Atif M, Sulaiman SA, Shafie AA, et al. Resource utilization pattern and cost of tuberculosis treatment from the provider and patient perspectives in the state of Penang, Malaysia. BMC Health Serv Res. Aug 19 2014;14:353. DOI:10.1186/1472-6963-14-353.
   PubMed Web of Science ®Google Scholar
• Chen DY, Yu F, Tuan LW, et al. Comparison of healthcare utilization and costs between ra patients receiving biological and conventional synthetic DMARDs: a nationwide population-based cohort study in Taiwan. Front Pharmacol. 2019;10:1214.
   PubMed Web of Science ®Google Scholar
• Dahlui M, Wan NC, Koon TS. Cost analysis of UMMC services: estimating the unit cost for outpatient and inpatient services. BMC Health Serv Res. 2012;12(Suppl 1):1–2.
   PubMedGoogle Scholar
• Jamsem E, Virta LJ, Hakala M, et al. The decline in joint replacement surgery in rheumatoid arthritisis associated with a concomitant increase in the intensity of anti-rheumatic therapy. Acta Orthop. 2013;84(4):331–337.
   PubMed Web of Science ®Google Scholar
• Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med. 2011 Jan;72(2):185–192. DOI:10.1016/j.socscimed.2010.10.026.
   PubMed Web of Science ®Google Scholar
• Braakman-Jansen LM, Taal E, Kuper IH, et al. Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA. Rheumatology (Oxford). 2012 Feb;51(2):354–361.
   PubMed Web of Science ®Google Scholar
• Goetzel RZ, Long SR, Ozminkowski RJ, et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. Journal of Occupational & Environmental Medicine. 2004 Apr;46(4):398–412. DOI:10.1097/01.jom.0000121151.40413.bd.
   PubMed Web of Science ®Google Scholar
• Sruamsiri R, Mahlich J, Tanaka E, et al. Productivity loss of Japanese patients with rheumatoid arthritis - a cross-sectional survey. Mod Rheumatol. 2018 May;28(3):482–489. DOI:10.1080/14397595.2017.1361893.
   PubMed Web of Science ®Google Scholar
• Lensberg BR, Drummond MF, Danchenko N, et al. Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. Clinicoecon Outcomes Res. 2013;5:565–573.
   PubMedGoogle Scholar
• Anis A, Zhang W, Emery P, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford). 2009 Oct;48(10):1283–1289.
   PubMed Web of Science ®Google Scholar
• Lee TJ, Park BH, Son HK, et al. Cost of illness and quality of life of patients with rheumatoid arthritis in South Korea. Value Health. 2012 Jan-Feb;15(1 Suppl):S43–9. DOI:10.1016/j.jval.2011.11.020.
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ. 2008 Jan;8(Suppl 2):S49–60. DOI:10.1007/s10198-007-0088-8.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Direskeneli H, Ertenli I, et al. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey. Clin Exp Rheumatol. 2016;34(6):1033–1037.
   PubMed Web of Science ®Google Scholar
• Alten R, Kruger K, Rellecke J, et al. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence. 2016;10:2217–2228.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Betteridge N, Brown TM, et al. Treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making. Patient Prefer Adherence. 2020;14:119–131.
   PubMed Web of Science ®Google Scholar
• Edel Y, Sagy I, Pokroy-Shapira E, et al. A cross-sectional survey on the preference of patients with rheumatoid arthritis for route of administration of disease-modifying anti-rheumatic drugs: oral target-specific versus parenteral biologic. Isr Med Assoc J. 2020 Mar;22(3):154–159.
   PubMed Web of Science ®Google Scholar
• Caswell H. Matrix population models. Vol. 1. Sunderland(MA): Sinauer Associates; 2000.
   Google Scholar
• Keyfitz N. On future population. J Am Stat Assoc. 1972 June 1;67(338):347–363.
   PubMed Web of Science ®Google Scholar
• Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998 Jan;13(1 Pt 1):1–7. DOI:10.2165/00019053-199813010-00001.
   PubMed Web of Science ®Google Scholar